Search Result

Results for "

BRD4+inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) AMPK (1) Apoptosis (14) Bcl-2 Family (2) Btk (1) c-Myc (8) CaMK (1) Caspase (1) CDK (2) DNA/RNA Synthesis (3) Epigenetic Reader Domain (69) ERK (1) FGFR (1) FLT3 (1) HIV (1) Interleukin Related (1) JAK (1) Ligands for Target Protein for PROTAC (7) PAK (1) PARP (3) PDGFR (1) Phosphatase (1) PI3K (5) Polo-like Kinase (PLK) (3) Reactive Oxygen Species (ROS) (2) Reference Standards (2) RET (1) ROS Kinase (1) STAT (1) TNF Receptor (1) TNK1 (1)
By Research Areas:	Cancer (59) Cardiovascular Disease (1) Infection (3) Inflammation/Immunology (14)

By Targets:

Akt (2)

AMPK (1)

Apoptosis (14)

Bcl-2 Family (2)

Btk (1)

c-Myc (8)

CaMK (1)

Caspase (1)

CDK (2)

DNA/RNA Synthesis (3)

Epigenetic Reader Domain (69)

ERK (1)

FGFR (1)

FLT3 (1)

HIV (1)

Interleukin Related (1)

JAK (1)

Ligands for Target Protein for PROTAC (7)

PAK (1)

PARP (3)

PDGFR (1)

Phosphatase (1)

PI3K (5)

Polo-like Kinase (PLK) (3)

Reactive Oxygen Species (ROS) (2)

Reference Standards (2)

RET (1)

ROS Kinase (1)

STAT (1)

TNF Receptor (1)

TNK1 (1)

By Research Areas:

Cancer (59)

Cardiovascular Disease (1)

Infection (3)

Inflammation/Immunology (14)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Natural
Products

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-50698

BI 2536 Maximum Cited Publications 59 Publications Verification	Polo-like Kinase (PLK) Epigenetic Reader Domain Apoptosis	Cancer
BI 2536 is a dual PLK1 and *BRD4* inhibitor with IC₅₀s of 0.83 and 25 nM, respectively . BI-2536 suppresses IFNB (encoding IFN-β) gene transcription ^[4].

HY-111139

MS417 4 Publications Verification GTPL7512	Epigenetic Reader Domain HIV	Infection Inflammation/Immunology
MS417 is a selective BET-specific *BRD4* inhibitor, binds to BRD4-BD1 and BRD4-BD2 with IC₅₀s of 30, 46 nM and K_ds of 36.1, 25.4 nM, respectively, with weak selectivity at CBP BRD (IC₅₀, 32.7 μM).

HY-14443

XMD8-92 10+ Cited Publications	Epigenetic Reader Domain ERK TNK1 CaMK	Cancer
XMD8-92 is a potent ERK5 (BMK1)/BRD4 inhibitor with K_ds of 80 and 190 nM, respectively. XMD8-92 inhibits DCAMKL2, PLK4 and TNK1 with K_ds of 190, 600 and 890 nM, respectively. Anti-cancer activity .

HY-107443

I-BET762 carboxylic acid Molibresib carboxylic acid; GSK525762A carboxylic acid; PROTAC BRD4-binding moiety 2	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
I-BET762 carboxylic acid (Molibresib carboxylic acid) is an I-BET762-based warhead ligand for conjugation reactions of PROTAC targeting on BET. I-BET762 carboxylic acid (Molibresib carboxylic acid) is a *BRD4* inhibitor with a pIC₅₀ of 5.1 .

HY-146208

BRD4 Inhibitor-20 1 Publications Verification	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-20 is a potent orally active bromodomain protein 4 (BRD4) inhibitor. BRD4 Inhibitor-20 has inhibitory activity for BRD4 (BD1) and BRD4 (BD2) with IC₅₀ values of 19 nM and 28 nM, respectively. BRD4 Inhibitor-20 also has anti-proliferation activities in cancer cell lines. BRD4 Inhibitor-20 can be used for the research of kinds of cancer, such as colon cancer .

HY-117491

BRD4 Inhibitor-10	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-10 (Compound II-25) is a potent *BRD4-BD1* inhibitor with an IC₅₀ of 8 nM. BRD4 Inhibitor-10 can be used to study diseases caused by abnormal or excessive cell proliferation, such as cancer .

HY-10220

SF1126	PI3K Apoptosis	Cancer
SF1126 is a relevant pan and dual first-in-class *PI3K/BRD4* inhibitor, has antitumor and anti-angiogenic activity. SF1126 is an RGDS-conjugated LY294002 proagent, which is designed to exhibit increased solubility and bind to specific integrins within the tumor compartment. SF1126 induces cell apoptosis .

HY-112150

ZL0454 2 Publications Verification	Epigenetic Reader Domain	Inflammation/Immunology
ZL0454 is a potent and selective Bromodomain-containing protein 4 (BRD4) inhibitor with an IC₅₀ of 49 and 32 nM for BD1 and BD2.

HY-111916

ODM-207 BET-IN-4	Epigenetic Reader Domain	Cancer
ODM-207 (BET-IN-4) is a potent BET bromodomain protein (BRD4) inhibitor, with an IC₅₀ of ≤ 1 μM .

HY-111102

FL-411 BRD4-IN-1	Epigenetic Reader Domain	Cancer
FL-411 is a potent and selective *BRD4* inhibitor with an IC₅₀ of 0.43±0.09 μM for *BRD4(1)*.

HY-112149

ZL0420	Epigenetic Reader Domain	Inflammation/Immunology
ZL0420 is a potent and selective bromodomain-containing protein 4 (BRD4) inhibitor with IC₅₀ values of 27 nM against BRD4 BD1 and 32 nM against BRD4 BD2.

HY-117997

UMB-32	Epigenetic Reader Domain	Cancer
UMB-32, a potent, selective *BRD4* inhibitor, binds BRD4 with the K_d of 550 nM, and IC₅₀ of 637 nM. UMB-32 also shows potency against TAF1, a bromodomain-containing transcription factor .

HY-158031

PLK1/BRD4-IN-5	Apoptosis Polo-like Kinase (PLK) Epigenetic Reader Domain	Cancer
PLK1/BRD4-IN-5 (Compound SC10) is an orally active PLK1 and *BRD4* inhibitor with IC₅₀ values of 0.3  nM and 60.8  nM, respectively. PLK1/BRD4-IN-5 can induce MV4-11 cell block in S phase and apoptosis) in a dose-dependent manner. PLK1/BRD4-IN-5 can be used in cancer research .

HY-146739

BRD4 Inhibitor-19	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-19 is a BET* inhibitor* with an IC₅₀ of 55 nM for BRD4-BD1. BRD4 Inhibitor-19 can be used for multiple myeloma research .

HY-112149A

(E/Z)-ZL0420	Epigenetic Reader Domain	Inflammation/Immunology Cancer
(E/Z)-ZL0420 is a racemic compound of (Z)-ZL0420 and (E)-ZL0420 isomers. (E)-ZL0420 is a potent and selective bromodomain-containing protein 4 (BRD4) inhibitor with IC₅₀ values of 27 nM against BRD4 BD1 and 32 nM against BRD4 BD2 .

HY-132130

BRD4 Inhibitor-13	Epigenetic Reader Domain	Inflammation/Immunology Cancer
BRD4 Inhibitor-13 (Compound 2) is a *BRD4* ligand, and can be used for research of cancer, inflammation.

HY-160499

BRD4 Inhibitor-30	Epigenetic Reader Domain	Cancer
BRD4 inhibitor-30 (Compound 1) is a *BRD4* inhibitor with a IC₅₀ value of 415 nM .

HY-143235

BRD4 Inhibitor-15	Epigenetic Reader Domain Apoptosis Bcl-2 Family Caspase c-Myc	Cancer
BRD4 Inhibitor-15 (compound 13) is a potent *BRD4* inhibitor, with an IC₅₀ of 18 nM. BRD4 Inhibitor-15 induces apoptosis of 22RV1 cells by regulating Bcl-2/Bax proteins and activating caspase-3 signaling pathway. BRD4 Inhibitor-15 down-regulates the c-Myc level in 22RV1 cells. BRD4 Inhibitor-15 can be used for prostate cancer research .

HY-130813

BET-IN-6	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
BET-IN-6 is a potent and high affnity *BRD2/BRD4* inhibitor. BET-IN-6 is the ligand for target protein BRD2/4, and is used for the systhesis of PROTAC BRD2/BRD4 degrader-1 (HY-130612) .

HY-147573

BRD4 Inhibitor-23	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-23 is a potent and orally active *BRD4* inhibitor with IC₅₀s of 6.21 nM and 1.44 nM for BRD4 BD-1 and BRD4 BD-2, respectively (WO2022033542A1; Example 1) .

HY-50698G

BI 2536	Polo-like Kinase (PLK) Apoptosis Epigenetic Reader Domain	Cancer
BI 2536 (GMP) is BI 2536 (HY-50698) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. BI 2536 is a dual PLK1 and *BRD4* inhibitor with IC₅₀s of 0.83 and 25 nM, respectively . BI-2536 suppresses IFNB (encoding IFN-β) gene transcription ^[4].

HY-167871

BRD4 Inhibitor-36	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-36 (Compound 185) is a *BRD4* inhibitor. BRD4 Inhibitor-36 can be used for the research of cancer .

HY-172095

BRD4 Inhibitor-39	Epigenetic Reader Domain Apoptosis	Cancer
BRD4 Inhibitor-39 (compound 12m) is an orally available *BRD4* inhibitor with an IC₅₀ value of 0.02 μM. BRD4 Inhibitor-39 induces apoptosis. BRD4 Inhibitor-39 has anti-tumor activity .

HY-157460

BRD4 Inhibitor-29	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-29 (SQ-17) is a *BRD4* inhibitor, with an IC₅₀ of <100 nM. BRD4 Inhibitor-29 shows antiproliferative effect against prostate cancer cells .

HY-W192171

BRD4 Inhibitor-34	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-34 (Compound 12a) is a *BRD4* inhibitor with an IC₅₀ of 24 μM .

HY-146660

BRD4 Inhibitor-18	c-Myc Epigenetic Reader Domain Apoptosis	Cancer
BRD4 Inhibitor-18 is a highly potent *BRD4* inhibitor with an IC₅₀ value of 110 nM. BRD4 Inhibitor-18 has a hydrophobic acetylcyclopentanyl side chain. BRD4 Inhibitor-18 can significantly suppress the proliferation of MV-4-11 cells with high BRD4 level. BRD4 Inhibitor-18 has apoptosis-promoting and G0/G1 cycle-arresting activity .

HY-151972

BRD4 Inhibitor-25	Epigenetic Reader Domain	Cardiovascular Disease Inflammation/Immunology Cancer
BRD4 Inhibitor-25 is a *BRD4* inhibitor with IC₅₀s of 0.82 μM, 1.94 μM for BD1 and BD2 domains of BRD4. BRD4 Inhibitor-25 induces apoptotic and autophagy cell death in ovarian cancer cells. BRD4 Inhibitor-25 can be used in the research of cancers, cardiovascular, neuromuscular and inflammatory disorders.

HY-155078

BRD4 Inhibitor-27	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-27 (compound 6) is a *BRD4* inhibitor with IC₅₀ of 9.6 and 11.3 μM for BRD4 BD1 and BRD4 BD2, respectively. BRD4 Inhibitor-27 has the potential to study cancer .

HY-160636

BRD4 Inhibitor-32	Epigenetic Reader Domain	Others
BRD4 Inhibitor-32 (example 15) is a BRD4 inhibitor that can be used in acute kidney disease and chronic kidney disease research .

HY-160660

BRD4 Inhibitor-33	Epigenetic Reader Domain	Others
BRD4 Inhibitor-33 (example 13) is a BRD4 inhibitor that can be used in acute kidney disease and chronic kidney disease research .

HY-174812

BRD4 ligand 8	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Inflammation/Immunology Cancer
BRD4 ligand 8 (Compound J558) is a *BRD4* inhibitor. BRD4 ligand 8 can be used for synthesis of PROTAC BRD4 Degrader-33 (HY-174811) .

HY-135236

OXFBD04	Epigenetic Reader Domain	Cancer
OXFBD04 is a potent and selective *BRD4* inhibitor with an IC₅₀ of 166 nM. OXFBD04 is a potent BET bromodomain ligand with additional modest affinity for the CREBBP bromodomain. OXFBD04 has anti-cancer activity .

HY-160634

BRD4 Inhibitor-31	Epigenetic Reader Domain	Infection Inflammation/Immunology Cancer
BRD4 Inhibitor-31 (Example 136) is a *BRD4* inhibitor (K_is: 0.234 μM and 0.295 μM for BRD4 BD1 and BRD4 BD2 respectively). BRD4 Inhibitor-31 can be used for research of inflammatory diseases, cancer, and AIDS .

HY-149519

BRD4 Inhibitor-28	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-28 (Compound 18) is an orally active *BRD4* Inhibitor. BRD4 Inhibitor-28 inhibits BRD40-BD1, BRD40-BD2 with IC₅₀s of 15, 55 nM. BRD4 Inhibitor-28 also inhibits BRD2-BD1, BRD3-BD1, BRDT-BD1 with IC₅₀s of 19, 25, 68 nM. BRD4 Inhibitor-28 has anti-melanoma activity .

HY-147202

BRD4 Inhibitor-24	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-24 (compound 3U) is a potent *BRD4* inhibitor, BRD4 Inhibitor-24 shows antitumor activity against MCF7 and K652 cells, with IC₅₀ values of 33.7 and 45.9 μM, respectively (extracted from patent CN107721975A) .

HY-145909

BRD4 Inhibitor-17	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-17 (Compound 5i) is a potent inhibitor of *BRD4* with an IC₅₀ of 0.33 μM. BRD4 Inhibitor-17 plays crucial role in regulating transcription of inflammatory, proliferation and cell cycle genes. BRD4 Inhibitor-17 serves as potential antidotes for arsenicals .

HY-115926

BRD4 Inhibitor-16	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-16 (Compound 4) is a potent inhibitor of bromodomain 4 (BRD4). Overexpression of bromodomain 4 (BRD4) is closely correlated with a variety of human cancers by regulating the histone post-translational modifications. BRD4 Inhibitor-16 represents a useful tool for explorative studies of BRD4 inhibition, such as an improved understanding of BRD4 inhibitor release-related information .

HY-W806047

BRD4 Inhibitor-37	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-37 is a compound with anticancer activity that has inhibitory activity against BRD4. BRD4 Inhibitor-37 has an IC50 of approximately 0.05-0.1 μM in binding assays and shows a GI50 of 0.1-0.3 μM in cell-based assays. The effect of BRD4 Inhibitor-37 on c-Myc, a downstream protein of BRD4, has been validated, demonstrating its ability to intervene in this signaling pathway. BRD4 Inhibitor-37 exhibits selectivity among five different bromodomain proteins, enhancing its potential as a BET protein inhibitor .

HY-N16067

Penipanoid C	Epigenetic Reader Domain	Inflammation/Immunology
Penipanoid C (Compound 9) is a *BRD4* inhibitor. Penipanoid C can be isolated from marine sediment-derived fungus Penicillium paneum SD-44. Penipanoid C has anti-inflammatory activity and cytotoxic activity against the SMMC-7721 cells. Penipanoid C can be used for inflammatory diseases research .

HY-153751

BRD4-IN-4	Epigenetic Reader Domain	Cancer
BRD4-IN-4 (Compound 1) is a *BRD4* inhibitor (IC₅₀=6.83 μM). BRD4-IN-4 selectively inhibits MV4-11 cell line proliferation and arrests cell at G1 phase. BRD4-IN-4 can be used for research of MLL leukemia .

HY-132128

BRD4 Inhibitor-12	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-12 (Compound 9) is a *BRD4* ligand, and can be used for research of cancer, infammation .

HY-144338

PARP1/BRD4-IN-1	Epigenetic Reader Domain PARP Apoptosis DNA/RNA Synthesis	Cancer
PARP1/BRD4-IN-1 is a potent and high selective *PARP1/BRD4** inhibitor* (IC₅₀s of 49 and 202 nM in PARP1 and BRD4, respectively). PARP1/BRD4-IN-1 represses the expression and activity of PARP1 and BRD4 to synergistically inhibit the malignant growth of pancreatic cancer cells .

HY-170686

BRD4 Inhibitor-38	Interleukin Related TNF Receptor Epigenetic Reader Domain	Inflammation/Immunology
BRD4 Inhibitor-38 (Compound 25) is an orally active inhibitor of *BRD4* with IC₅₀ values of 3.64 μM and 0.12 μM against BRD4 BD1 and BRD4 BD2, respectively. BRD4 Inhibitor-38 also exhibits anti-inflammatory activity, with an IC₅₀ value of 1.98 μM for inhibiting nitric oxide (NO) production .

HY-173062

BRD4 Inhibitor-40	Epigenetic Reader Domain c-Myc	Others
BRD4 Inhibitor-40 (Compound 23) is the inhibitor for BRD that inhibits *BRD4-BD1, BRD4-BD2, BRD2-BD1* and BRD2-BD2 with IC₅₀s of 16.1, 142.18, 29.35 and 302.35 nM, respectively. BRD4 Inhibitor-40 modulates the expression of c-Myc and p21, arrests cell cycle at G1 phase, inhibits Pkd1-null (PN) renal cystic epithelial cells, and blocks the renal cysts formation in Madin-Darby canine kidney and embryonic kidney vesicle models. BRD4 Inhibitor-40 exhibits renal cysts inhibitory activity in mouse models .

HY-175033

BRD4-IN-11	Epigenetic Reader Domain Phosphatase c-Myc Apoptosis	Inflammation/Immunology
BRD4-IN-11 is an orally active and selective *BRD4* inhibitor (IC₅₀ = 26.35 nM (BD1), IC₅₀ = 72.81 nM (BD2)). BRD4-IN-11 is approximately 3- to 18-fold more potent against *BRD4* than againstBRD2, BRD3, and BRDT. BRD4-IN-11 enhances H2S release and inhibits the upregulation of fibrotic markers (α-SMA and fibronectin), c-Myc, and CDC25B. BRD4-IN-11 reduces apoptosis in LO2 hepatocytes. BRD4-IN-11 significantly improves liver and lung function in a hepatopulmonary fibrosis model and can be used to study hepatopulmonary fibrosis .

HY-124859

CeMMEC2	Epigenetic Reader Domain	Cancer
CeMMEC2 is a direct *BRD4* inhibitor with an IC₅₀ of 0.9 μM.

HY-160672

BRD4-IN-8	Epigenetic Reader Domain	Cancer
BRD4-IN-8 (Example 13b) is a *BRD4* inhibitor .

HY-141843

BRD4-IN-2	Epigenetic Reader Domain	Inflammation/Immunology
BRD4-IN-2 is a bromodomain *BRD4* inhibitor with an IC₅₀ value of 9.9 nM.

HY-160670

BRD4-IN-6	Epigenetic Reader Domain	Cancer
BRD4-IN-6 (compound 116) is a *BRD4* inhibitor (extracted from patent CN107721975A).

HY-160671

BRD4-IN-7	Epigenetic Reader Domain	Cancer
BRD4-IN-7 (compound 120) is a *BRD4* inhibitor(extracted from patent CN107721975A).

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N16067

Penipanoid C	Alkaloids Marine natural products Quinoline Alkaloids Marine microorganism Source Classification	Epigenetic Reader Domain
Penipanoid C (Compound 9) is a *BRD4* inhibitor. Penipanoid C can be isolated from marine sediment-derived fungus Penicillium paneum SD-44. Penipanoid C has anti-inflammatory activity and cytotoxic activity against the SMMC-7721 cells. Penipanoid C can be used for inflammatory diseases research .

HY-N15522

Bi-magnolignan	Magnoliaceae Houpoea officinalis (Rehder & E. H. Wilson) N. H. Xia & C. Y. Wu Phenols Polyphenols Plants Source Classification	Epigenetic Reader Domain
Bi-magnolignan is a *BRD4* inhibitor that induces DNA damage and apoptosis. Bi-magnolignan inhibits HCT116 cell proliferation with an IC₅₀ value of 2.9 μM .

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-50698G

BI 2536	Polo-like Kinase (PLK) Apoptosis Epigenetic Reader Domain	Cancer
BI 2536 (GMP) is BI 2536 (HY-50698) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. BI 2536 is a dual PLK1 and *BRD4* inhibitor with IC₅₀s of 0.83 and 25 nM, respectively . BI-2536 suppresses IFNB (encoding IFN-β) gene transcription ^[4].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks